Study #2017-0224IBRUTINIB
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
MD Anderson Study Status
Not Accepting
Treatment Agent
Ibrutinib
Description
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Study phase:
Phase IV
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-791-1647
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.